Trials / Completed
CompletedNCT06812429
Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin (DAPA) | Participants will receive 10mg of Dapagliflozin per day for three days. |
Timeline
- Start date
- 2024-05-08
- Primary completion
- 2025-04-05
- Completion
- 2025-04-05
- First posted
- 2025-02-06
- Last updated
- 2026-01-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06812429. Inclusion in this directory is not an endorsement.